Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

June 1st 2021

The new drug application seeking the approval of a unique formulation of sodium thiosulfate for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmetastatic solid tumors has been resubmitted to the FDA.

Afamitresgene Autoleucel Elicits Encouraging Responses in Heavily Pretreated Sarcoma

May 26th 2021

Afamitresgene autoleucel was found be efficacious with favorable tolerability in heavily pretreated patients with advanced synovial sarcoma or myxoid/round cell liposarcoma, according to data from phase 2 SPEARHEAD-1 trial.

Next Generation of PDGFR Inhibitors Makes Headway in GIST

May 25th 2021

Dysregulated platelet-derived growth factor receptor signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.

Trametinib/Ganitumab Combo Shows Early Promise in Pediatric Rhabdomyosarcoma

May 24th 2021

MEK inhibition combined with an anti-IGFR1 agent shrank tumors in pediatric PAX fusion–negative rhabdomyosarcoma.

The Expanding Concern Surrounding Abdominal Metastases in Osteosarcoma

May 20th 2021

Early detection and quick intervention of abdominal metastases in patients with osteosarcoma could be a tactic to improve patient outcomes as well as palliative care.

Dr. Tap on the Effects of the COVID-19 Pandemic on Sarcoma

May 17th 2021

William D. Tap, MD, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in Osteosarcomas

May 4th 2021

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies

April 29th 2021

Dr. Riedel and Dr. Van Tine discuss the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.

Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab Shows Early Promise in DSRCT

April 29th 2021

Intraperitoneal radioimmunotherapy with the anti-B7H3 murine monoclonal antibody 131I-omburtamab was well tolerated with low radiation exposure to normal organs, making it a feasible option to combine with other therapies in patients with desmoplastic small round cell tumor.

Observation May Be Preferrable to Surgery in Certain Cases of Desmoid Tumor Fibromatosis

April 29th 2021

The local recurrence rate after surgical excision was similar to the rate of progression with active surveillance in patients with extra-abdominal desmoid tumor fibromatosis, suggesting that observation may be sufficient in some cases.

Dr. Gorlick on the Potential of ADCs in Osteosarcoma

April 20th 2021

Richard Gorlick, MD, discusses the potential of antibody-drug conjugates in patients with osteosarcoma.

Selinexor Improves QoL in Advanced Unresectable Dedifferentiated Liposarcoma

April 19th 2021

Selinexor resulted in lower rates and slower worsening of pain in patients with advanced unresectable dedifferentiated liposarcoma vs placebo, and may represent a novel option to provide convenience, improved adherence, and reduced caregiver burden vs existing parenteral therapies.

Making the Choice: Osseus Reattachment of the Greater Trochanter Vs Soft Tissue–Only Abductor Repair in Bone Cancers

April 16th 2021

Reattaching the greater trochanter to the proximal femur endoprosthesis did not show an improvement in Trendelburg gait or reliance on an assistive ambulatory device vs a soft tissue–only abductor repair in patients with bone cancers.

Dr. Gorlick on Methods for Identifying Immunotherapeutic Targets in Osteosarcomas

April 15th 2021

Richard Gorlick, MD, highlights methods for identifying immunotherapeutic targets in osteosarcomas.

Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers

April 13th 2021

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.

Dr. Gorlick on the Use of Integrative Surfaceome Profiling to Identify Targets in Osteosarcomas

April 12th 2021

Richard Gorlick, MD, discussed results from a study examining the use of integrative surfaceome profiling to identify immunotherapeutic targets in patients with osteosarcomas.

Dr. Trent on the Role of Avapritinib in PDGFRA Exon 18+ GIST

April 9th 2021

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

Dr. Murphy on Remaining Questions With SBRT in Pediatric Sarcoma

April 8th 2021

Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.

Clinical Benefit of Ripretinib Expands as Investigators Consider Future Directions

April 8th 2021

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

Dr. Murphy on the Clinical Implications of Pazopanib Plus SBRT in Pediatric Sarcoma

April 7th 2021

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.